Olfactory Receptor 51E2 Activation by β-Ionone Induces a Senescence-Like Phenotype and Increases Susceptibility to Senolytic Treatment in Colorectal Cancer
Aging and Disease · 2026
DOI: 10.14336/ad.2026.1095 ↗Abstract
Olfactory receptor 51E2 (OR51E2) is markedly downregulated in colorectal cancer (CRC), yet its functional activation by its natural agonist, β-ionone, suppresses CRC cell growth. In this study, we investigated the tumor-suppressive effects of β-ionone-mediated OR51E2 activation using human CRC cell lines (SW480, SW620, and RKO) and patient-derived organoids (PDOs). We demonstrate that β-ionone treatment stimulates intracellular calcium levels in an OR51E2-dependent manner, upregulating MAPK-directed phosphatases (DUSP1/2/4 and PPP1CA). This calcium-dependent phosphatase activation suppresses the MEK1/2-ERK1/2 signaling axis, leading to G0/G1 cell cycle arrest via the downregulation of CDK2/4/6 and cyclin A/D1. Concurrently, OR51E2 activation induces a senescence-like phenotype, evidenced by increased senescence-associated β-galactosidase activity, chromatin remodeling (reduced LAMIN B1 and increased H3K27me3), and upregulated p16/p21 expression alongside senescence-associated secretory phenotype (SASP) factors. These phenotypic and mechanistic findings were fully recapitulated in CRC-PDOs representing distinct clinical subtypes. Crucially, the residual senescence-like cell population showed increased susceptibility to dasatinib plus quercetin (DQ), which reduced senescence-associated markers and increased apoptosis. Collectively, this study demonstrates that OR51E2 activation coordinates a heterogeneous cell-fate decision encompassing both apoptosis and a senescence-like phenotype. Our findings highlight ectopic olfactory receptor signaling as an underexplored mechanism of tumor suppression and provide in vitro evidence for a sequential approach in CRC in which β-ionone-mediated OR51E2 activation induces a senescence-like state followed by senolytic treatment.
EUVIMED